Cutler Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,000
| Closed | -$30K | – | 5618 |
|
|
2022
Q3 | $30K | Sell |
2,000
-300
| -13% | -$3.49K | ﹤0.01% | 2314 |
|
|
2022
Q2 | $17K | Sell |
2,300
-300
| -12% | -$2.11K | ﹤0.01% | 2831 |
|
|
2022
Q1 | $23K | Hold |
2,600
| – | – | ﹤0.01% | 2950 |
|
|
2021
Q4 | $18K | Hold |
2,600
| – | – | ﹤0.01% | 3228 |
|
|
2021
Q3 | $29K | Hold |
2,600
| – | – | ﹤0.01% | 3021 |
|
|
2021
Q2 | $41K | Hold |
2,600
| – | – | ﹤0.01% | 2674 |
|
|
2021
Q1 | $46K | Hold |
2,600
| – | – | ﹤0.01% | 2482 |
|
|
2020
Q4 | $35K | Sell |
2,600
-300
| -10% | -$3.63K | ﹤0.01% | 2266 |
|
|
2020
Q3 | $34K | Hold |
2,900
| – | – | ﹤0.01% | 2072 |
|
|
2020
Q2 | $42K | Hold |
2,900
| – | – | ﹤0.01% | 1869 |
|
|
2020
Q1 | $39K | Buy |
+2,900
| New | +$55K | ﹤0.01% | 1893 |
|
|
2019
Q1 | – | Sell |
-400
| Closed | -$17.6K | – | 4980 |
|
|
2018
Q4 | $14K | Sell |
400
-100
| -20% | -$4.69K | ﹤0.01% | 2368 |
|
|
2018
Q3 | $30K | Sell |
500
-920
| -65% | -$59.1K | ﹤0.01% | 1974 |
|
|
2018
Q2 | $95K | Buy |
+1,420
| New | +$79.5K | 0.01% | 1185 |
|
|
2018
Q1 | – | Sell |
-10,742
| Closed | -$601K | – | 5497 |
|
|
2017
Q4 | $641K | Buy |
10,742
+8,221
| +326% | +$499K | 0.03% | 453 |
|
|
2017
Q3 | $122K | Sell |
2,521
-3,696
| -59% | -$202K | ﹤0.01% | 1503 |
|
|
2017
Q2 | $326K | Buy |
6,217
+3,922
| +171% | +$183K | 0.01% | 947 |
|
|
2017
Q1 | $104K | Sell |
2,295
-345
| -13% | -$15.4K | ﹤0.01% | 1702 |
|
|
2016
Q4 | $99K | Sell |
2,640
-21,300
| -89% | -$805K | ﹤0.01% | 1918 |
|
|
2016
Q3 | $903K | Buy |
23,940
+14,840
| +163% | +$327K | 0.04% | 374 |
|
|
2016
Q2 | $160K | Buy |
9,100
+3,647
| +67% | +$59K | 0.01% | 1292 |
|
|
2016
Q1 | $66K | Buy |
5,453
+241
| +5% | +$3.81K | ﹤0.01% | 2032 |
|
|
2015
Q4 | $126K | Buy |
+5,212
| New | +$122K | 0.01% | 1567 |
|
Cutler Group's AERI Position: Q4 2022 in Review
Cutler Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 2,000 shares — an estimated $30K sold.
Cutler Group first reported a position in AERI in Q4 2015 and held it in 23 quarters. The position peaked at $903K in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Cutler Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Cutler Group sold 2,000 Aerie Pharmaceuticals shares in Q4 2022, an estimated $30K.
- Cutler Group first reported a position in Aerie Pharmaceuticals in Q4 2015 and held it in 23 quarters.
- Cutler Group's Aerie Pharmaceuticals position peaked at $903K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.